To the content
4 . 2022

Treatment of endotoxemia and prevention of shock with the help of multiple adsorption of lipopolysaccharide: description of a clinical case and literature review

Abstract

Endotoxemia is a common cause of shock and poor outcomes in sepsis. This paper describes a case of recovery of a young patient from sepsis caused by pan-resistant bacterial flora after a car injury with aortic rupture. Multiple adsorption of lipopolysaccharide was used as part of complex therapy to treat endotoxemia.

Material and methods. A17-year old patient K., diagnosed with a condition after polytrauma, accompanied by aortic rupture, complicated by multiple organ dysfunction and sepsis (SOFA score up to 14 points): coma I-II; paresis of the gastrointestinal tract; respiratory failure due to pneumonia; acute kidney injury with anuria; acute liver failure; thrombocytopenia. The sources of infection were: translocation of bacteria; sinusitis, meningoencephalitis. In bacterial blood cultures, the presence of both gram-positive and gram-negative multi-resistant flora was identified. The level of procalcitonin, depending on the activity of the infectious process, ranged from 35 to 336 ng/ml. Surgical interventions to drain and sanitize the focus of infection as well as repeated changes in antibiotic therapy were performed in order to control the infectious process. The level of endotoxemia was assessed by endotoxin activity assay (EAA from 0.7 to 1). 60 hours of polymyxin B (PMX) hemoperfusion (5 sessions) were performed in conjunction with continuous use of the Oxiris universal set.

Results. In 100 days after hospitalization, the patient had no signs of infection, was conscious, breathing spontaneously, had partially restored motor and speech functions and was transferred to a rehabilitation center. After each PMX hemoperfusion [a 12-hour (h) session followed by a 12-h break before the next 12-h session], EAA value reduced or didn’t increase above 0.7. After the first 12 hours of use, it was possible to withdraw vasopressors, oxygenation index significantly increased, signs of shock were no longer observed; after 2 sessions peristalsis was restored. According to the literature, repeated PMX hemoperfusion sessions have been used in the treatment of patients with septic shock associated with endotoxemia caused by translocation of the intestinal flora, and in patients with an infectious focus in the lungs or other organs, after transplantation of parenchymal organs and as a replacement for antibiotic therapy. The indications for the procedure were: an increase of EAA over 0.6; high SOFA values; the presence of gram-negative microorganisms.

Conclusion. The heterogeneity of the course of sepsis requires a multidisciplinary, complex and targeted treatment. Patients with severe multiple organ dysfunction and severe endotoxemia represent the most unfavorable cohort of patients with sepsis and can be identified using a blood lipopolysaccharide activity test. EAA values in blood also makes it possible to determine the nature of the bacterial flora, monitor the presence of an infection focus, the adequacy of its sanitation and the effectiveness of the therapy. PMX hemoperfusion effectively corrects the level of endotoxemia and, accordingly, allow us to control the occurrence of septic shock.

Keywords:heterogeneity; sepsis; lipopodisaccharide (endotoxin); EAA test; polymyxin B hemoperfusion (PMX hemoperfusion)

Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Babaev M.A., Eremenko A.A., Zyulyaeva T.P., Grekova M.S., Grin O.O., Balalaeva M.A., Komnov R.D., Urbanov A.V., Sorokina L.S., Koshek E.A., Polyakova P.V., Dmitrieva S.S. Treatment of endotoxemia and prevention of shock with the help of multiple adsorption of lipopolysaccharide: description of a clinical case and literature review. Clinical and Experimental Surgery. Petrovsky Journal. 2022; 10 (4): 117–24. DOI: https://doi.org/10.33029/2308-1198-2022-10-4-117-124  (in Russian)

References

1.     Kellum J., et al. Endotoxemic sepsis: clinical features and therapy. J Transl Crit Care Med. 2022; 4 (1): 13.

2.     Putzu A., et al. Blood purification and mortality in sepsis and septic shock. Anesthesiology. 2019; 131 (3): 580–93.

3.     Marshall J.C., et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004; 190 (3): 527–34.

4.     Fujimori K., Tarasawa K., Fushimi K. Effects of polymyxin b hemoperfusion on septic shock patients requiring noradrenaline: analysis of a nationwide administrative database in Japan. Blood Purif. 2021; 50 (4–5): 560–5.

5.     Fujimori K., Tarasawa K., Fushimi K. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study. Ann Intensive Care. 2021; 11 (1): 141.

6.     Ricci Z., et al. Hemoperfusion in the intensive care unit. Intensive Care Med. 2022; 48 (10): 1397–408.

7.     Stanski N.L., Wong H.R. Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol. 2020; 16 (1): 20–31.

8.     Rimmel T., Kellum J.A. Clinical review: blood purification for sepsis. Crit Care. 2011; 15 (1): 205.

9.     Wiersinga W.J., et al. Host innate immune responses to sepsis. Virulence. 2914; 5 (1): 36–44.

10. Dargent A., et al. Improved quantification of plasma lipopolysaccharide (LPS) burden in sepsis using 3-hydroxy myristate (3HM): a cohort study. Intensive Care Med. 2019; 45 (11): 1678–80.

11. Schultz P., et al. High-dose CytoSorb hemoadsorption is associated with improved survival in patients with septic shock: a retrospective cohort study. J Crit Care. 2021; 64: 184–92.

12. Dellinger R.P., et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018; 320 (14): 1455–63.

13. Aoki H., Tani T. Treatment of sepsis by extracorporeal elimination of endotoxin using polyrnyxin B-immobilized fiber. Am J Surg. 1994; 167 (4): 412–7.

14. Nozaka Kimiyasu, et al. Case report of septic shock after operation improved by 4th polymyxin-B immobilized fiber therapy (PMX-DHP). Jpn J Crit Care  Endotoxemia. 2003; 7: 190–3.

15. Novelli G., et al. Clinical results of treatment of postsurgical endotoxin-mediated sepsis with polymyxin-B direct hemoperfusion. Transplant Proc. 2010; 42 (4): 1021–4.

16. Rybalko A., et al. Case report: successful use of extracorporeal therapies after ECMO resuscitation in a pediatric kidney transplant recipient. Front Pediatr. 2020; 8: 593123.

17. Takeda S., et al. Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intensive Care Med. 2010; 36 (5): 906–7.

18. Novelli G., et al. Polymixin-B hemoperfusion in a case intolerant to conventional antibiotic therapy. J Biomed Sci Eng. 2012; 5 (3): 101–3.

19. Wei Q., et al. Successful treatment of crush syndrome complicated with multiple organ dysfunction syndrome using hybrid continuous renal replacement therapy. Blood Purif. 2009; 28 (3): 175–80.

20. Evans L., et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021; 47 (11): 1181–247.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Sergey L. Dzemeshkevich
MD, Professor (Moscow, Russia)

Journals of «GEOTAR-Media»